AI Technology Group Inc. Liquidation Value

AI Technology Group Inc. (AIPG) is a Nevada shell with no revenue, no cash, no tangible productive assets, and a going-concern qualification. At September 30, 2025, total assets consist solely of $989 in prepaid expenses, which under liquidation haircuts recover at approximately $940 (95% on a prepaid basis, though in practice prepaid expenses in a wind-down scenario often recover nothing if they represent subscription-type services). Total liabilities stand at $76,165, composed of $8,790 in accounts payable and $67,375 due to a related party (the new CEO, Marcus Johnson, or entities he controls). Both obligations remain at face value in liquidation. Net liquidation recovery to equity is therefore approximately negative $75,000 to negative $76,165, consistent with MFFAIS-reported CLV/LLV/OLV of -$76,165. There is zero recovery to equity on any liquidation scenario.

Since the prior comparable period (December 31, 2024 audited balance sheet), total liabilities increased from $46,732 to $76,165 — a $29,433 increase driven by $20,644 in new related-party advances (funding operating cash outflows) and $8,790 in newly accrued accounts payable. The accumulated deficit deepened from $4,354,844 to $4,388,733, a $33,889 deterioration reflecting nine months of G&A spend (transfer agent, accounting, legal, OTC fees, consulting) with no revenue offset.

Two structural items compound the recovery analysis. First, a change of control occurred on July 29, 2025: the former controlling shareholders (Wan Jia Lin and Yuanmei Lin) sold 1,264,234 shares (78.85% of outstanding) to a vehicle controlled by Marcus Johnson, the new CEO/CFO/director. The pre-existing related-party loan of $46,732 was also transferred to a Johnson-controlled entity, meaning the entire $67,375 related-party payable now sits with the new controller. This payable is unsecured, non-interest-bearing, with no fixed repayment terms — its face-value treatment in liquidation is the correct approach, but the counterparty concentration risk is notable. Second, subsequent to the period (October 7, 2025), the company issued 27,958,695 restricted common shares — a 17.4x increase in share count — to shareholders of Biomed360 Solutions Corp. under a definitive agreement dated August 1, 2025 that also contemplates acquisition of AVM Biotechnology Inc. This massive dilutive issuance is not reflected on the September 30, 2025 balance sheet but is material to any equity recovery analysis on a post-period basis. The filing also discloses that as of November 14, 2025, the related-party payable has grown to $80,299. Filing discusses the proposed acquisition and convertible loan obligations to AVM in MD&A and notes, but does not separately XBRL-tag these contingent obligations or the post-period share issuance in the balance sheet context. Prior period filing provided is from the Energenx era (September 30, 2008) and is not comparable for QoQ analysis; comparison is performed against the December 31, 2024 audited figures presented within this filing.